Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients

Table 2

The IL-6 levels of COVID-19 patients before and after TCZ treatment (pg/mL).

Case no.	Before TCZ therapy	After TCZ therapy							Clinical outcomes
		Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	12.84	24.40	648.5			2932			Death
2	210.9	339.6	314.2	254.2	92.43	103.5		83.48	Clinical improvement
3	27.91		122.9		101.4				Clinical improvement
4	18.60				146.2				Clinical improvement
5	44.45	370.6			55.29			16.25	Clinical improvement
6	7.42	104.6				110.1			Clinical improvement
7	56.18	36.15		60.99				37.88	Clinical improvement
8	32.01	646.6				521.7		135.5	Clinical improvement
9	57.32				23.30			19.77	Clinical improvement
10	100.4	454.6	1245	1521		1177	940	1308	Death
11	27.90	63.72						84.56	Clinical improvement
12	20.57		84.87		54.87				Clinical improvement
13	9.42	1207		615.9			155.3		Clinical aggravation

The normal value of IL-6 ranges from 0.00 to 7.00 pg/mL.